Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Core Insights - Adaptive Biotechnologies Corporation is showcasing the increasing interventional use of its clonoSEQ test at the 67th American Society of Hematology Annual Meeting, with 90 abstracts featuring clonoSEQ data, including 17 that demonstrate its role in guiding clinical actions for blood cancer patient care [1][9] Group 1: Clinical Applications and Studies - The phase II EndRAD study supports the use of next-generation sequencing (NGS) measurable residual disease (MRD) status prior to allogeneic hematopoietic cell transplantation (HCT) to select non-total body irradiation (TBI) conditioning approaches, showing excellent event-free and overall survival in 51 NGS MRD negative patients [2][3] - Across hematologic malignancies, clonoSEQ MRD status is utilized by healthcare providers to guide clinical decisions, with presentations demonstrating its application in tailoring treatment intensity and duration [3][9] - A phase III AURIGA study involving 200 newly diagnosed multiple myeloma (MM) patients showed that deep MRD responses correlated with improved progression-free survival, and intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates [7] Group 2: Abstracts and Research Findings - A total of 32 abstracts on multiple myeloma will be presented, focusing on MRD assessment of treatment response and real-world data linking MRD status to clinical outcomes [7] - In non-Hodgkin lymphoma (NHL), 15 abstracts will explore MRD to understand treatment response depth and guide therapy, including a study on de-escalating therapy in frail older adults with diffuse large B-cell lymphoma (DLBCL) [7] - Data from a phase II study of 80 previously untreated chronic lymphocytic leukemia (CLL) patients indicated that time-limited therapy achieved deep and durable remissions based on MRD assessment [8] Group 3: clonoSEQ Overview - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, and is also available for other lymphoid cancers as a CLIA-validated laboratory developed test [10][11] - The test identifies and quantifies DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, providing standardized and sensitive results that inform treatment decisions and predict outcomes [11]